ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer

Arjun Balar, MD
Published Online:1:42 PM, Tue October 25, 2016

Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.